miR ‑505 suppresses prostate cancer progression by targeting NRCAM.

In conclusion, the present study revealed the inhibitory effects of miR‑505 on PCa tumorigenesis, which potentially occur by targeting NRCAM. The combined analysis of NRCAM and miR‑505 may predict disease progression in patients with PCa following radical prostatectomy. PMID: 31322225 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research